Published by Global Banking & Finance Review®
Posted on November 10, 2025
2 min readLast updated: January 21, 2026
Add as preferred source on GoogleNovo Nordisk partners with Emcure to launch Poviztra, a new weight-loss drug in India, aiming to expand market reach amid competition.
(Reuters) -Novo Nordisk has partnered with India's Emcure Pharmaceuticals to exclusively distribute and market its weight-loss drug under a new brand in the country, the companies said on Monday.
Under the agreement, the Danish drugmaker will sell Poviztra 2.4 milligram (mg) semaglutide injection in India as a separate brand of its blockbuster weight-loss treatment Wegovy.
Shares of Emcure Pharma rose following the announcement, trading 6.5% higher at 1,451 rupees.
Novo Nordisk launched Wegovy in India in June, three months after Eli Lilly introduced its competing weight-loss product Mounjaro in the world's most populous nation.
Wegovy's 2.4 mg dose is priced at 26,015 rupees for a month's supply in India, while pricing for Poviztra was not disclosed.
"This partnership is part of Novo Nordisk India's efforts to ensure its innovative treatments reach a greater number of patients in India," the Danish company said in an exchange filing.
Last month, Eli Lilly also partnered with Cipla to sell its weight-loss drug under a separate brand in India.
(Reporting by Manvi Pant in Bengaluru; Editing by Mrigank Dhaniwala and Sherry Jacob-Phillips)
A weight-loss drug is a medication designed to help individuals reduce body weight by suppressing appetite, increasing metabolism, or preventing fat absorption.
Market response refers to how consumers and investors react to a new product launch, including changes in sales, stock prices, and overall market interest.
A blockbuster drug is a medication that generates annual sales of over $1 billion, often due to its widespread use and effectiveness.
Explore more articles in the Headlines category
